Mechanisms of action of aminoglutethimide as endocrine therapy of breast cancer.
about
The influence of aminoglutethimide and its analogue rogletimide on peripheral aromatisation in breast cancerDrug metabolism by leukocytes and its role in drug-induced lupus and other idiosyncratic drug reactions.The therapeutic potential of aromatase inhibitors.Aromatase inhibitors: clinical pharmacology and therapeutic implications in breast cancer.Progestins in breast cancer treatment. A review.Plasma and urinary oestrogens in breast cancer patients on treatment with 4-hydroxyandrostenedione.Combined treatment with 4-hydroxyandrostenedione and aminoglutethimide: effects on aromatase inhibition and oestrogen suppression.The influence of CGS 16949A on peripheral aromatisation in breast cancer patients.Endocrinological and clinical evaluation of two doses of formestane in advanced breast cancerInfluence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer.Alterations in the production rate and the metabolism of oestrone and oestrone sulphate in breast cancer patients treated with aminoglutethimide.Treatment of breast cancer with aromatase inhibitors--current status and future prospectsAromatase inhibition 2013: clinical state of the art and questions that remain to be solvedStrength and weakness of phase I to IV trials, with an emphasis on translational aspects.Additive endocrine therapy for advanced breast cancer - back to the future.Evolution of endocrine adjuvant therapy for early breast cancer.New endocrine drugs for treatment of advanced breast cancer.Aromatase inhibitors and other novel agents in breast cancer treatment.Aromatase inhibition for breast cancer treatment.[New inhibitors of aromatase: synthesis and biological activity of pyridyl-substituted phenanthrenone derivatives]Plasma estrone and estrone sulphate in breast cancer patients treated with the aromatase inhibitor CGS 16949A.
P2860
Q24683853-EECBDE9E-0A2A-46C9-8AF5-1B2F43A008EAQ33396340-6FBB1C7C-BB5A-46F1-8647-491B35F251F4Q35073327-7AB4C253-829D-44BB-9731-9941F328C1BDQ35349533-AE772671-5C1F-458C-A4D2-93A4B50F066EQ35651439-F4C6958F-6F46-4FB5-BE0B-B4D76EE32085Q35977200-EC7DA7F4-F664-435C-948B-C9A149932043Q35979241-49337FBE-155A-4747-A20E-4DBF1465C2A1Q35984346-B239F281-C648-4997-A5E9-683D230DD497Q36079441-912EEBC9-D046-4186-ADE0-CB697FA4E13AQ36138879-55E78DD3-6496-4C95-B43C-3E4E9E6DD17BQ36468052-6A21A7EF-E91F-497F-88C1-10DFF889D022Q36468107-89EC1922-EAF0-4846-AF1B-6FD4581C1FA9Q36946008-6BB212B5-F45B-4296-A156-4919756FD58EQ37039810-81780789-AFF4-4AF2-BF4B-2D03DBFDB548Q37622884-F61E107C-7570-4F4C-BB86-61CA937D56EAQ37725970-070E9237-56E7-40FC-AB6C-E7A45FA44B77Q37938324-B5C6DF4F-1595-44F2-8F31-AEEBBD30FD2FQ40409345-6CD70B4A-29A3-4271-BFA7-023D0A6798AAQ41463872-8D6CEA1E-2E5D-4AA0-88E1-1A5AE6FC2C5EQ44124340-3B7976B1-C6D0-41C2-8D0F-41FCEF4361EBQ46316666-B09EF959-8031-4147-B316-60230F996C96
P2860
Mechanisms of action of aminoglutethimide as endocrine therapy of breast cancer.
description
1988 nî lūn-bûn
@nan
1988年の論文
@ja
1988年論文
@yue
1988年論文
@zh-hant
1988年論文
@zh-hk
1988年論文
@zh-mo
1988年論文
@zh-tw
1988年论文
@wuu
1988年论文
@zh
1988年论文
@zh-cn
name
Mechanisms of action of aminoglutethimide as endocrine therapy of breast cancer.
@en
Mechanisms of action of aminoglutethimide as endocrine therapy of breast cancer.
@nl
type
label
Mechanisms of action of aminoglutethimide as endocrine therapy of breast cancer.
@en
Mechanisms of action of aminoglutethimide as endocrine therapy of breast cancer.
@nl
prefLabel
Mechanisms of action of aminoglutethimide as endocrine therapy of breast cancer.
@en
Mechanisms of action of aminoglutethimide as endocrine therapy of breast cancer.
@nl
P1433
P1476
Mechanisms of action of aminoglutethimide as endocrine therapy of breast cancer.
@en
P304
P356
10.2165/00003495-198835060-00005
P577
1988-06-01T00:00:00Z
P6179
1043457247